Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.92)
# 192
Out of 5,004 analysts
104
Total ratings
79.2%
Success rate
51.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Rated: Buy | $240 | $204.97 | +17.09% | 12 | Aug 27, 2026 | |
| ZYME Zymeworks | Rated: Buy | $40 | $26.52 | +50.83% | 9 | Aug 25, 2026 | |
| CELC Celcuity | Reiterated: Buy | $166 | $79.52 | +108.75% | 7 | Aug 14, 2026 | |
| STRO Sutro Biopharma | Rated: Buy | $27 → $49 | $15.98 | +206.63% | 3 | Aug 13, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 → $23 | $19.21 | +19.73% | 11 | Aug 12, 2026 | |
| EXEL Exelixis | Rated: Hold | $49 → $50 | $58.16 | -14.03% | 5 | Aug 6, 2026 | |
| RCUS Arcus Biosciences | Rated: Hold | $23 → $26 | $24.97 | +4.12% | 9 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $48 | $36.74 | +30.65% | 6 | Aug 5, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Rated: Buy | $74 → $87 | $75.08 | +15.88% | 16 | Jul 29, 2026 | |
| GMAB Genmab | Rated: Buy | $40 | $35.32 | +13.25% | 7 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $17.47 | +20.21% | 9 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5 | $2.70 | +85.19% | 1 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $30.72 | +95.31% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $23.80 | +13.45% | 6 | Oct 23, 2025 |
Revolution Medicines
Aug 27, 2026
Rated: Buy
Price Target: $240
Current: $204.97
Upside: +17.09%
Zymeworks
Aug 25, 2026
Rated: Buy
Price Target: $40
Current: $26.52
Upside: +50.83%
Celcuity
Aug 14, 2026
Reiterated: Buy
Price Target: $166
Current: $79.52
Upside: +108.75%
Sutro Biopharma
Aug 13, 2026
Rated: Buy
Price Target: $27 → $49
Current: $15.98
Upside: +206.63%
Bicara Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $16 → $23
Current: $19.21
Upside: +19.73%
Exelixis
Aug 6, 2026
Rated: Hold
Price Target: $49 → $50
Current: $58.16
Upside: -14.03%
Arcus Biosciences
Aug 6, 2026
Rated: Hold
Price Target: $23 → $26
Current: $24.97
Upside: +4.12%
IDEAYA Biosciences
Aug 5, 2026
Reiterated: Buy
Price Target: $48
Current: $36.74
Upside: +30.65%
Kiniksa Pharmaceuticals International,
Jul 29, 2026
Rated: Buy
Price Target: $74 → $87
Current: $75.08
Upside: +15.88%
Genmab
Jun 29, 2026
Rated: Buy
Price Target: $40
Current: $35.32
Upside: +13.25%
May 19, 2026
Reiterated: Buy
Price Target: $21
Current: $17.47
Upside: +20.21%
May 13, 2026
Rated: Hold
Price Target: $5
Current: $2.70
Upside: +85.19%
Apr 14, 2026
Reiterated: Buy
Price Target: $60
Current: $30.72
Upside: +95.31%
Oct 23, 2025
Reiterated: Buy
Price Target: $27
Current: $23.80
Upside: +13.45%